An investigation for investors in NASDAQ:CPXX shares was announced concerning whether the takeover of Princeton, NJ based Celator Pharmaceuticals. for $30.25 per share is unfair to NASDAQ:CPXX stockholders.
Investors who purchased shares of Celator Pharmaceuticals Inc (NASDAQ:CPXX) and currently hold any of those NASDAQ:CPXX shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain directors of Celator Pharmaceuticals Inc breached their fiduciary duties owed to NASDAQ:CPXX investors in connection with the proposed acquisition.
On May 31, 2016, Jazz Pharmaceuticals plc and Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that they have entered into an agreement for Jazz Pharmaceuticals to acquire Celator Pharmaceuticals Inc (NASDAQ:CPXX) for $30.25 per share in cash, or approximately $1.5 billion.
However, the investigation concerns whether the offer is unfair to NASDAQ:CPXX stockholders. More specifically, the investigation concerns whether the Celator Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders’ best interests in connection with the proposed sale.
Shares of Celator Pharmaceuticals Inc (NASDAQ:CPXX) closed on June 10, 2016, at $30.24 per share.
Those who are current investors in NASDAQ:CPXX shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com